Department of Gastroenterology, Marmara University, School of Medicine, 34662 Altunizade, Istanbul, Turkey.
World J Gastroenterol. 2009 Sep 21;15(35):4387-91. doi: 10.3748/wjg.15.4387.
Nonalcoholic fatty liver disease (NAFLD) remains a leading cause of chronic liver disease. In the context of NAFLD, the presence of nonalcoholic steatohepatitis (NASH) portends an adverse prognosis with greater risk of liver fibrosis and cirrhosis. Although liver biopsy is the keystone of patient management in NAFLD, it is also increasingly clear that such evaluation has its limitations. The availability of biochemical markers of NAFLD and NASH has tremendous potential to radically alter management strategies for these conditions, as well as to monitor disease activity. Our article provides an overview of biomarker discovery and selection in the setting of NAFLD and highlights future directions in the field.
非酒精性脂肪性肝病（NAFLD）仍然是慢性肝病的主要原因。在 NAFLD 的背景下，非酒精性脂肪性肝炎（NASH）的存在预示着预后不良，肝纤维化和肝硬化的风险更大。尽管肝活检是 NAFLD 患者管理的基石，但越来越明显的是，这种评估也有其局限性。NAFLD 和 NASH 的生化标志物的可用性具有极大的潜力，可以彻底改变这些疾病的管理策略，并监测疾病活动。我们的文章概述了 NAFLD 背景下的生物标志物发现和选择，并强调了该领域的未来方向。
